Trinity Biotech (TRIB) EBIT (2009 - 2024)

Trinity Biotech has disclosed EBIT across 16 years of filings, most recently posting -$11.5 million for Q4 2024.

• EBIT for Q4 2024 came in at -$11.5 million, down 204.66% year-over-year; the trailing twelve-month figure through Dec 2024 was -$21.2 million (up 21.76% YoY), and the FY2025 annual result was -$15.8 million, up 25.4% from the prior year.
• EBIT came in at -$11.5 million for Q4 2024 at Trinity Biotech, down from -$2.6 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $9.1 million in Q3 2020 to a low of -$14.9 million in Q2 2023.
• The 5-year median for EBIT is -$2.2 million (2022), against an average of -$2.0 million.
• Across the five-year window, EBIT soared 581.55% in 2020 and tumbled 1548.85% in 2022, its largest moves.
• Trinity Biotech's EBIT stood at $9.1 million in 2020, then slumped by 93.79% to $563000.0 in 2021, then sank by 1548.85% to -$8.2 million in 2022, then soared by 53.67% to -$3.8 million in 2023, then tumbled by 204.66% to -$11.5 million in 2024.
• The last three EBIT figures came in at -$11.5 million (Q4 2024), -$2.6 million (Q3 2024), and -$4.1 million (Q2 2024), per Business Quant data.